-
Dec 11, 2024 | 
jdsupra.com | Steven Schnelle
Until recently, Massachusetts was the only state that did not maintain a licensing regime for nonresident pharmacies (i.e., out-of-state pharmacies shipping drugs into the state).
-
Dec 11, 2024 | 
openlegalblogarchive.org | Steven Schnelle
The 2024 election results will create significant tailwinds for Republican legislative and regulatory priorities in US Congress, federal agencies, and state houses across the country. This client alert considers the outlook for pharmacy regulation under the second incoming Trump administration and a unified Republican Congress, as well as state-level pharmacy policies that may advance as […]
-
Dec 10, 2024 | 
mondaq.com | Cheese Consumers |Steven Schnelle
The 2024 election results will create significant tailwinds for
Republican legislative and regulatory priorities in US Congress,
federal agencies, and state houses across the country. This On
the Subject considers the outlook for pharmacy regulation
under the second incoming Trump administration and a unified
Republican Congress, as well as state-level pharmacy policies that
may advance as Republican public policy momentum builds.
-
Dec 10, 2024 | 
natlawreview.com | Steven Schnelle
The 2024 election results will create significant tailwinds for Republican legislative and regulatory priorities in US Congress, federal agencies, and state houses across the country. This On the Subject considers the outlook for pharmacy regulation under the second incoming Trump administration and a unified Republican Congress, as well as state-level pharmacy policies that may advance as Republican public policy momentum builds.
-
Dec 10, 2024 | 
employeebenefitsblog.com | Steven Schnelle |Jae Lee
By and on December 10, 2024 Posted In Employee Benefits, Health and Welfare Plans The 2024 election results will create significant tailwinds for Republican legislative and regulatory priorities in US Congress, federal agencies, and state houses across the country.
-
Dec 6, 2024 | 
jdsupra.com | Jae Hyun Lee |Steven Schnelle
The 2024 election results will create significant tailwinds for Republican legislative and regulatory priorities in US Congress, federal agencies, and state houses across the country. This On the Subject considers the outlook for pharmacy regulation under the second incoming Trump administration and a unified Republican Congress, as well as state-level pharmacy policies that may advance as Republican public policy momentum builds.
-
Dec 7, 2023 | 
law360.com | Emily Cook |Steven Schnelle |Kelsey Reinhardt
ADVERTISEMENT Don't want ads? Subscribe or login now. By Emily Cook, Steven Schnelle and Kelsey Reinhardt (December 7, 2023, 5:22 PM EST) -- On Nov. 3, the U.S. District Court for the District of South Carolina issued a landmark order in Genesis Health Care Inc. v. Becerra, a case analyzing the definition of a "patient" under the Section 340B program statute....
-
Nov 17, 2023 | 
jdsupra.com | Emily Cook |Kelsey Reinhardt |Steven Schnelle
On November 3, 2023, the US District Court for the District of South Carolina issued a landmark order in Genesis Health Care, Inc. v. Becerra, a case analyzing the definition of a “patient” under the 340B Program Statute. The court concluded that the government’s restrictive interpretation of the term was contrary to the plain language of the 340B Statute and would frustrate the goals of the 340B Program.
-
Oct 31, 2023 | 
jdsupra.com | Emily Cook |Paul Hughes |Steven Schnelle
On October 26, 2023, the Health Resources and Services Administration (HRSA) issued a Notice to “inform and remind” 340B Program covered entities that to be considered eligible for the 340B program, an off-site outpatient facility of a covered entity (commonly referred to as a “child site”) must be reimbursable on the covered entity’s most recently filed Medicare cost report (MCR) and listed in the Office of Pharmacy Affairs Information System (OPAIS) as a child site of the covered entity.
-
Oct 30, 2023 | 
jdsupra.com | Emily Cook |Steven Schnelle
On October 26, the Health Resources and Services Administration (HRSA) published a Federal Register notice addressing the use of 340B drugs at off-campus hospital outpatient locations that have not yet appeared on a filed Medicare cost report.
